SCHEMBL814063

SCHEMBL814063

Cc1cccc(C)c1C(N)CN(CC(N)c1c(C(C)C)cccc1C(C)C)[Co](Cl)Cl

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.31
SCN4A P35499 3/20 0.31
MAOA P21397 2/20 0.31
SCN1A P35498 2/20 0.31
SCN5A Q14524 2/20 0.31
SCN9A Q15858 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
TSHR P16473 2/20 0.31
HTR2B P41595 2/20 0.31
MAOB P27338 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
NFKB1 P19838 1/20 0.31
KCNK3 O14649 1/20 0.31
CACNA1F O60840 1/20 0.31
KCNK2 O95069 1/20 0.31
GBA1 P04062 1/20 0.31
HTR2A P28223 1/20 0.31
SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL813076 0.93 GABRA1 (0.35) LMNACYP1A2CYP3A4TSHRHTR2B
SCHEMBL814291 0.91
SCHEMBL813207 0.91 SLC6A2 (0.31) LMNASLC6A4SLC6A2
SCHEMBL813066 0.91
SCHEMBL813547 0.89 SCN4A (0.33) LMNASCN4AMAOASCN1ASCN5A
SCHEMBL813567 0.86 SCN4A (0.31) LMNASCN4AMAOASCN1ASCN5A
SCHEMBL814750 0.83 CFD (0.37) LMNACYP1A2CYP3A4TSHRHTR2B
SCHEMBL813677 0.82 SLC6A2 (0.34) SLC6A4SLC6A2
SCHEMBL812915 0.80 ALDH1A1 (0.32) CYP3A4GABRA1GABRB2
SCHEMBL812455 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058372-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-11-15 US disclosed
US-20080319147-A1 Catalyst Composition II EXXONMOBIL CHEMICAL PATENTS INC. 2008-12-25 US disclosed
US-7371803-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-05-13 US disclosed
US-20070066776-A1 Catalyst composition II SOLAN GREGORY A 2007-03-22 US disclosed
US-7189791-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-03-13 US disclosed
US-20040266961-A1 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266961-A1 Catalyst composition II MLX, CBX2, BMX LMNA 25/4885SCN4A 2798/4885MAOA 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.